Treatment of lymphoid tumors with anti-idiotype antibodies

Stevenson, G T; Stevenson, Freda K.

doi:10.1007/bf01857369

Cited by 26 publications

(3 citation statements)

References 50 publications

(39 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent preclinical and clinical studies have presented convincing evidences that monoclonal antibodies recognizing cell surface antigens can mediate effective antitumor activity [98,99] through different mechanisms: complement-mediated lysis, antibody-dependent cellular cytotoxicity and direct induction of apoptosis pathways.…”

Section: Humoral Immune Responsementioning

confidence: 99%

Immunology of Gynecologic Neoplasms: Analysis of the Prognostic Significance of the Immune Status

Bellati¹,

Visconti

Napoletano³

et al. 2009

CCDT

View full text Add to dashboard Cite

Gynecologic Oncology has changed in the last few decades. An increasing proportion of patients is benefiting from long term survival although patients diagnosed with advanced disease suffer from a poor prognosis. Unfortunately, several recent studies are confirming that changing the combinations of "traditional" cytotoxic drugs is unlikely to obtain a real breakthrough in survival rates. Furthermore, there is discouraging data regarding consolidation therapies. It is, therefore, necessary to identify new target therapies with a minimal impact on quality of life. It is likely that new breakthroughs are only going to be achieved when changes in therapies are tailored to the entire natural history of the disease and on specific patient characteristic's. Since the discovery that tumor infiltrating lymphocytes represent an independent prognostic factor in ovarian cancer patients, several researchers have dedicated their attention to cancer immune response in order to identify prognostic factors and immunological targets. Analyses on immunophenotype at diagnosis and throughout the entire course of treatment are currently ongoing and are giving the new diagnostic, prognostic and therapeutic tools to the physicians. Furthermore new antigens and new vaccination strategies are being investigated. Encouraging data on selected patient populations have been observed recently. The objective of the present review is to define the immunology of women affected by gynecological malignancies and describe new immunological targets for prognostic and therapeutic use.

show abstract

Section: Humoral Immune Responsementioning

confidence: 99%

Immunology of Gynecologic Neoplasms: Analysis of the Prognostic Significance of the Immune Status

Bellati¹,

Visconti

Napoletano³

et al. 2009

CCDT

View full text Add to dashboard Cite

show abstract

“…The method described in this report does not rely on the prior isolation of Id-bearing Ig. The number of tumor cells needed for immunization is therefore much smaller than that necessary when Fab fragments from tumor cell surface Ig are used, in which case lo1' tumor cells (equivalent to a tissue volume of 20 cm3) are needed [23].…”

Section: Discussionmentioning

confidence: 99%

Mouse monoclonal antibodies against the idiotype of human B cell non‐Hodgkin lymphomas: production, characterization and use to monitor the progress of disease

Rankin¹,

Hekman²

1984

Eur J Immunol

View full text Add to dashboard Cite

Four monoclonal anti-idiotype (Id) antibodies against B cell non-Hodgkin lymphomas have been made by a simple and rapid procedure for hybridoma production that does not use isolated Id-carrying immunoglobulin. Mice were immunized with plasma membranes from the tumor cells. Screening of hybridoma colonies using an autologous T cell line and a cell line bearing the same immunoglobulins as the malignant lymphocytes as well as the capping phenomenon on the patient's own tumor cells, allowed selection of hybridomas producing anti-Id antibodies. These anti-Id antibodies were used to demonstrate variations in the circulating malignant cell population and fluctuations in the level of circulating free Id.

show abstract

“…B cell lymphomas contain unique idiotype (Id) determinants on their immunoglobulin (Ig) molecules. The Id is the collection of unique antigenic determinants present on Ig variable regions and can serve as tumour antigens on lymphomas (Stevenson & Stevenson, 1983). Active vaccination with Id is under investigation.…”

mentioning

confidence: 99%

Molecular rescue of tumour‐specific T cell receptor idiotype from T cell lymphomas

Reddy

Levy

2004

Br J Haematol

View full text Add to dashboard Cite

Summary The T cell receptor (TCR) idiotype on T cell lymphomas can serve as a vaccine target. To clone the relevant genes, 5′ rapid amplification of cDNA ends (RACE) was performed on 13 T cell lymphomas and nine control samples. Two polymerase chain reactions (PCR) were performed for each TCR chain (α and β) and the proportion of the clonal TCR sequence over the total number of TCR sequences was calculated. For α, the average proportions were 0·43 vs. 0·05. For β these were 0·44 and 0·04. The TCR was identified in 10 of 13 lymphoma samples.

show abstract

Treatment of lymphoid tumors with anti-idiotype antibodies

Cited by 26 publications

References 50 publications

Immunology of Gynecologic Neoplasms: Analysis of the Prognostic Significance of the Immune Status

Immunology of Gynecologic Neoplasms: Analysis of the Prognostic Significance of the Immune Status

Mouse monoclonal antibodies against the idiotype of human B cell non‐Hodgkin lymphomas: production, characterization and use to monitor the progress of disease

Molecular rescue of tumour‐specific T cell receptor idiotype from T cell lymphomas

Contact Info

Product

Resources

About